Tübingen-based CureVac AG, a biopharmaceutical company and pioneer in the preclinical and clinical development of mRNA-based vaccines and therapeutics, confirms that all internal efforts are currently focused on the development of a vaccine against the novel coronavirus - with the aim of reaching, helping and protecting people and patients worldwide.
The Company says it is in contact with numerous organizations, in particular the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private initiative to accelerate the development of vaccines against emerging infectious diseases, and numerous government agencies. CureVac refrains from commenting on current media speculation and clearly rejects any allegations that the company or its technology is being sold.
Based on its mechanism of action, CureVac considers mRNA to be one of the most potent molecules to provide a rapid and efficient solution for pandemic scenarios, such as the novel coronavirus. With 20 years of experience and deep scientific understanding, CureVac is applying its vaccine platform and focusing on the development of an effective, safe and fast producing vaccine against the novel coronavirus.
Only recently, CureVac published positive results from a Phase 1 study with the mRNA-based rabies vaccine CV7202. These data show the complete protection of humans after two vaccinations with the lowest dose of 1 µg mRNA vaccine (1 millionth of a gram) each. These results are encouraging, especially in view of the fact that people around the world can be provided with it in a pandemic scenario.
The company has long and extensive manufacturing experience and has been producing mRNA-based vaccines and therapeutics since 2006. CureVac is working to expand its production capacities to be able to provide up to billions of doses for pandemic situations such as Covid-19, depending on the individual vaccine dose required.
Mariola Fotin-Mleczek, Chief Technology Officer at CureVac, comments: "Nature has created mechanisms to activate the immune system against infections. With our unique mRNA technology, we can mimic nature and provide the body with the information it needs to fight the virus. The combination of our knowledge of mRNA, our understanding of the disease and our production technologies makes CureVac a unique player in the fight against any infectious disease, whether seasonal or pandemic in nature.
CureVac is a leading biopharmaceutical company in the field of mRNA (messenger RNA) technology. With 20 years of expertise, CureVac is working to develop, optimize and test this versatile molecule for medical use in clinical trials. The principle of CureVac's proprietary technology is based on the use of mRNA as an information carrier to guide the human body to produce appropriately encoded proteins that can be used to fight a variety of diseases. The company applies its technologies to the development of cancer therapies, antibody therapies, prophylactic vaccines and the treatment of rare diseases. CureVac has received significant equity investments, including from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac also collaborates with multinational corporations and organizations such as Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, CEPI and the Bill & Melinda Gates Foundation. CureVac is headquartered in Tübingen, Germany, with additional offices in Frankfurt, Germany and Boston, MA, USA.
CureVac is a member of the Förderkreis Standortmarketing.